Theriva Biologics Inc. (NYSE AMERICAN: TOVX)
$0.27
-0.0026 ( -0.95% ) 67.0K
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
Market Data
Open
$0.27
Previous close
$0.27
Volume
67.0K
Market cap
$4.68M
Day range
$0.26 - $0.28
52 week range
$0.20 - $0.75
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 16 | Feb 07, 2024 |
8-k | 8K-related | 54 | Jan 08, 2024 |
4 | Insider transactions | 1 | Dec 15, 2023 |
4 | Insider transactions | 1 | Dec 15, 2023 |
4 | Insider transactions | 1 | Dec 15, 2023 |
4 | Insider transactions | 1 | Dec 15, 2023 |
10-q | Quarterly Reports | 75 | Nov 13, 2023 |
8-k | 8K-related | 14 | Nov 13, 2023 |
8-k | 8K-related | 16 | Oct 23, 2023 |
8-k | 8K-related | 15 | Oct 17, 2023 |